Abstract:Farnesoid X receptor (FXR) is a promising target for drug discovery against nonalcoholic fatty liver disease (NAFLD). However, no FXR agonist has been approved for NAFLD so far. The R & D of FXR agonists are somewhat hindered by the lack of effective and safe chemotypes. To this end, we developed a multi-stage computational workflow to screen the Specs and ChemDiv chemical library for FXR agonists, which consisted of machine learning (ML)-based classifiers, shape-based and electrostatic-based models, a FRED-based molecular docking protocol, an ADMET prediction protocol and substructure search. As a result, we identified a novel chemotype that has never been reported before, with compound XJ02862 (ChemDiv ID: Y020-6413) as the representative. By designing an asymmetric synthesis strategy, we were able to prepare four isomers of compound XJ02862. Interestingly, one of the isomers, 2-((S)-1-((2S,4R)-2-methyl-4-(phenylamino)-3,4-dihydroquinolin-1(2H)-yl)-1-oxopropan-2-yl)hexahydro-1H-isoindole-1,3(2H)-dione (XJ02862-S2), showed potent FXR agonistic activity in HEK293T cells. The molecular docking, molecular dynamics simulations and site-directed mutagenesis suggested the hydrogen bond between compound XJ02862-S2 and HIS294 of FXR is essential for ligand binding. We further demonstrated that compound XJ02862-S2 had no agonistic effect on TGR5. Further biological experiments have shown that compound XJ02862-S2 could ameliorate hypercholesterolemia, hepatic steatosis, hyperglycemia, insulin resistance (IR) in high-fat-diet induced obese (DIO) mice. In term of molecular mechanism, compound XJ02862-S2 regulates the expression of FXR downstream genes involved in lipogenesis, cholesterol transport and bile acid biosynthesis and transport. Taken together, we have discovered a novel chemotype as potent FXR agonists for NAFLD by computational modeling, chemical synthesis and biological evaluation.

Discovery of a novel oxime ether scaffold as potent and orally bioavailable free fatty acid receptor 1 agonists

Design, Synthesis, and Biological Evaluation of Novel FFA1 Partial Agonists Bearing Oxime Ether Scaffold

Machine learning- and structure-based discovery of a novel chemotype as FXR agonists for potential treatment of nonalcoholic fatty liver disease

Identification of Highly Potent and Orally Available Free Fatty Acid Receptor 1 Agonists Bearing Isoxazole Scaffold

Structure-based design of free fatty acid receptor 1 agonists bearing non-biphenyl scaffold

Discovery of Novel Pyrrole-Based Scaffold As Potent and Orally Bioavailable Free Fatty Acid Receptor 1 Agonists for the Treatment of Type 2 Diabetes

Structure-based Optimization of Free Fatty Acid Receptor 1 Agonists Bearing Thiazole Scaffold.

Synthesis and Biological Evaluation of Phenoxyacetic Acid Derivatives As Novel Free Fatty Acid Receptor 1 Agonists.

Discovery of Novel Free Fatty Acid Receptor 1 Agonists Bearing Triazole Core Via Click Chemistry

Design, Synthesis and Biological Activity of Phenoxyacetic Acid Derivatives As Novel Free Fatty Acid Receptor 1 Agonists.

Design, Synthesis and Structure-Activity Relationship Studies of Novel Free Fatty Acid Receptor 1 Agonists Bearing Amide Linker.

Design, Synthesis and Structure-Activity Relationship Studies of Novel Phenoxyacetamide-Based Free Fatty Acid Receptor 1 Agonists for the Treatment of Type 2 Diabetes

Design, synthesis and biological evaluations of novel farnesoid X receptor (FXR) agonists

Design, Synthesis and Structure-Activity Relationship Studies of New Thiazole-Based Free Fatty Acid Receptor 1 Agonists for the Treatment of Type 2 Diabetes

Discovery of Phenylsulfonyl Acetic Acid Derivatives with Improved Efficacy and Safety As Potent Free Fatty Acid Receptor 1 Agonists for the Treatment of Type 2 Diabetes

Design, synthesis and biological evaluation of novel FFA1/GPR40 agonists: New breakthrough in an old scaffold

Design, Synthesis and Biological Activity of Deuterium-Based FFA1 Agonists with Improved Pharmacokinetic Profiles

Design, Synthesis, and Biological Evaluation of Deuterated Phenylpropionic Acid Derivatives As Potent and Long-Acting Free Fatty Acid Receptor 1 Agonists.

Design, Synthesis, and Biological Evaluation of Novel Pan Agonists of FFA1, PPARγ and PPARδ.

Design, Synthesis, and Biological Evaluation of Novel Dual FFA1 (gpr40)/pparδ Agonists As Potential Anti-Diabetic Agents.

Novel Phenoxyalkanoic Acid Derivatives as Free Fatty Acid Receptor 4 Agonists for Treating Type 2 Diabetes Mellitus